Splenic dendritic cell involvement in FXR-mediated amelioration of DSS colitis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1862, Issue 2, 2016, Pages 166-173

  Massafra, Vittoria ^a   Ijssennagger, Noortje ^a   Plantinga, Maud ^a   Milona, Alexandra ^a   Ramos Pittol, José M ^a   Boes, Marianne ^a   van Mil, Saskia W C ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Dendritic cells; Farnesoid X receptor; Inflammatory Bowel Disease

Indexed keywords

FARNESOID X RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; OBETICHOLIC ACID; PROTEIN; PROTEIN MADCAM1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; FLUORESCENCE ACTIVATED CELL SORTING; GRANULOCYTE; IMMUNE RESPONSE; MALE; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL;

EID: 84947998835     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.11.001     Document Type: Article

References (39)

1. Podolsky D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347:417-429.
2. Farrell R.J., Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J. Endourol. 2003, 178:339-346.
3. Ben-Horin S., Kopylov U., Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun. Rev. 2014, 13:24-30.
4. Podolsky D.K. Selective adhesion-molecule therapy and inflammatory bowel disease-a tale of Janus?. N. Engl. J. Med. 2005, 353:1965-1968.
5. Wendt E., Keshav S. CCR9 antagonism: potential in the treatment of inflammatory bowel disease. Clin. Exp. Gastroenterol. 2015, 8:119-130.
6. Gadaleta R.M., Cariello M., Sabba C., et al. Tissue-specific actions of FXR in metabolism and cancer. Biochim. Biophys. Acta 1851, 2015:30-39.
7. Gadaleta R.M., van Erpecum K.J., Oldenburg B., et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011, 60:463-472.
8. Vavassori P., Mencarelli A., Renga B., et al. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 2009, 183:6251-6261.
9. Berndt B.E., Zhang M., Chen G.H., et al. The role of dendritic cells in the development of acute dextran sulfate sodium colitis. J. Immunol. 2007, 179:6255-6262.
10. Kiss M., Czimmerer Z., Nagy L. The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: from physiology to pathology. J. Allergy Clin. Immunol. 2013, 132:264-286.
11. Cario E., Gerken G., Podolsky D.K. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007, 132:1359-1374.
12. Xia C.Q., Kao K.J. Effect of CXC chemokine platelet factor 4 on differentiation and function of monocyte-derived dendritic cells. Int. Immunol. 2003, 15:1007-1015.
13. Hartmann G., Weiner G.J., Krieg A.M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:9305-9310.
14. Darzynkiewicz Z., Bruno S., Del Bino G., et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992, 13:795-808.
15. Lantier L., Lacroix-Lamande S., Potiron L., et al. Intestinal CD103+ dendritic cells are key players in the innate immune control of Cryptosporidium parvum infection in neonatal mice. PLoS Pathog. 2013, 9.
16. Farkas S., Hornung M., Sattler C., et al. Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int. J. Color. Dis. 2006, 21:71-78.
17. Wurbel M.A., McIntire M.G., Dwyer P., et al. CCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitis. PLoS One 2011, 6.
18. Wermers J.D., McNamee E.N., Wurbel M.A., et al. The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice. Gastroenterology 2011, 140:1526-1535. (e3).
19. Chassaing B., Aitken J.D., Malleshappa M., et al. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 2014, 104. (Unit 15 25).
20. Okayasu I., Hatakeyama S., Yamada M., et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98:694-702.
21. Kitajima S., Morimoto M., Sagara E., et al. Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice. Exp. Anim. 2001, 50:387-395.
22. Fukata M., Michelsen K.S., Eri R., et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G1055-G1065.
23. Rescigno M., Urbano M., Valzasina B., et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat. Immunol. 2001, 2:361-367.
24. Abe K., Nguyen K.P., Fine S.D., et al. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17022-17027.
25. Hakansson A., Tormo-Badia N., Baridi A., et al. Immunological alteration and changes of gut microbiota after dextran sulfate sodium (DSS) administration in mice. Clin. Exp. Med. 2015, 15:107-120.
26. Zhang R., Ito S., Nishio N., et al. Dextran sulphate sodium increases splenic Gr1(+)CD11b(+) cells which accelerate recovery from colitis following intravenous transplantation. Clin. Exp. Immunol. 2011, 164:417-427.
27. Wang Y., Han G., Chen Y., et al. Protective role of tumor necrosis factor (TNF) receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemic inflammatory response. Lab. Investig. 2013, 93:1024-1035.
28. Ingersoll M.A., Platt A.M., Potteaux S., et al. Monocyte trafficking in acute and chronic inflammation. Trends Immunol. 2011, 32:470-477.
29. Swirski F.K., Nahrendorf M., Etzrodt M., et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009, 325:612-616.
30. Schote A.B., Turner J.D., Schiltz J., et al. Nuclear receptors in human immune cells: expression and correlations. Mol. Immunol. 2007, 44:1436-1445.
31. Renga B., Migliorati M., Mencarelli A., et al. Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-gamma-STAT-1 pathway in macrophages. Biochim. Biophys. Acta 1792, 2009:564-573.
32. McMahan R.H., Wang X.X., Cheng L.L., et al. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J. Biolumin. Chemilumin. 2013, 288:11761-11770.
33. Chami B., Yeung A.W., van Vreden C., et al. The role of CXCR3 in DSS-induced colitis. PLoS One 2014, 9.
34. Johansson-Lindbom B., Svensson M., Wurbel M.A., et al. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J. Exp. Med. 2003, 198:963-969.
35. Kato S., Hokari R., Matsuzaki K., et al. Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J. Pharmacol. Exp. Ther. 2000, 295:183-189.
36. Kiesler P., Fuss I.J., Strober W. Experimental models of inflammatory bowel diseases. Cell Mol. Gastroenterol. Hepatol. 2015, 1:154-170.
37. Sasaki M., Mathis J.M., Jennings M.H., et al. Reversal of experimental colitis disease activity in mice following administration of an adenoviral IL-10 vector. J. Inflamm. 2005, 2(13). (Lond).
38. Knod J.L., Crawford K., Dusing M., et al. Mouse strain influences angiogenic response to dextran sodium sulfate-induced colitis. J. Surg. Res. 2014, 190:47-54.
39. Rossi O., Khan M.T., Schwarzer M., et al. Faecalibacterium prausnitzii strain HTF-F and its extracellular polymeric matrix attenuate clinical parameters in DSS-induced colitis. PLoS One 2015, 10.